Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point
Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
From: Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data (Pediatr Nephrol, 2026 Oct) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 1, 7, 3, 6, 6.
New guidelines and consensus this year
- [KDIGO-Update: Treatment of ANCA vasculitis]Dtsch Med Wochenschr2025 Nov
All papers from the last 12 months
209 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Guilu Erxian oral liquid alleviates oligoasthenospermia via the mitochondria-complement-NETs networkJ Ethnopharmacol2026 Dec 6PMID 42349767
- Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort studyJ Crit Care2026 DecPMID 42526359
- Real-World Outcomes of Iptacopan in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative GlomerulonephritisKidney Int Rep2026 NovPMID 42876601
- Complement targeting in autoimmune diseasesCurr Opin Hematol2026 Nov 1PMID 42710066Review
- Real-World Use of Avacopan in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Early and Long-Term Clinical, Renal, and Patient-Reported Outcomes in an Italian Rheumatology-Nephrology NetworkACR Open Rheumatol2026 OctPMID 42860759
- Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal InvolvementKidney Int Rep2026 OctPMID 42761229
- Complosome as a key modulator of cellular senescence, aging and age-related diseasesAgeing Res Rev2026 OctPMID 42521026Review
- Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidneyKidney Int2026 OctPMID 42486191
- Pneumococcal HUS in infancy masking DGKE-related thrombotic microangiopathy with secondary hemophagocytic lymphohistiocytosisPediatr Nephrol2026 OctPMID 41979714
- Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world dataPediatr Nephrol2026 OctPMID 41838094Meta-analysisSystematic review
More nephrology trends
All specialties →Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Home dialysis
Home haemodialysis and peritoneal dialysis.
Key point: Core interventions to reduce PD-related infections focus on surveillance, standardized staff and patient training, infection prevention assessments, and antimicrobial prophylaxis.
HIF-PH inhibitors for anaemia
Oral drugs such as roxadustat for anaemia of kidney disease.
Key point: HIF-PHIs such as roxadustat are reserved for non-dialysis CKD when erythropoiesis-stimulating agents are unsuitable, given potential risks and limited long-term data.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(iptacopan[tiab] OR avacopan[tiab] OR "complement inhibit*"[tiab]) AND (kidney[tiab] OR glomerul*[tiab] OR nephr*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.